In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Closing the Loop: Progress on the Artificial Pancreas Project
Dietary Energy Density, Energy Intake & Managing Obesity and Diabetes
What is the Relationship Between Insulin Sensitivity and Puberty?
The Increasing Role of the Pharmacist in Diabetes Care
Can A Whole Grain Diet Help Manage Diabetes?
The Relationship Between Diabetes and Periodontal Disease
The Benefits of Physical Therapy for Patients With Diabetes
Improving the Care and Management of Hispanics with Diabetes
The Certified Diabetes Educator: A Key Role in the Diabetes Team
Gastric Surgery for Bypassing Type 2 Diabetes
Initiating Insulin Therapy for Type 2 Diabetes
Addressing the Unique Challenges for Elderly Patients with Diabetes
Integrative Medicine and Managing Diabetes
The Benefits of Moderate Weight Loss in Diabetes
The Benefits of TZDs for Early Type 2 Diabetes
Addressing the Global Diabetes Epidemic
Advances in Continuous Glucose Monitoring
Oral Agents for Diabetes: What to Choose and When
Skin Care for Patients Living with Diabetes
Challenges in Diagnosis and Treatment of Diabetes in Asian Americans
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video